TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9165189
Drug: Monthly mode
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly mode (MM) during a 3‐month period
Study: 3618289
Drug: Amitriptyline (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (mean final dose: 130 mg)
Study: 18816010
Drug: Individual cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual cognitive-behavioral treatment (CBT)
Study: 16600235
Drug: Past oral
Normalized name: Oral Paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Past oral contraceptive use
Study: 7662901
Drug: Metoclopramide (MCP)
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide (MCP) 10 mg
Study: 1330398
Drug: Quinapril 20
Normalized name: quinapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 20 mg administered at 8 AM
Study: 1330398
Drug: Quinapril 20
Normalized name: quinapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 20 mg administered at 10 PM
Study: 24717698
Drug: Palonosetron 0.0025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron 0.0025 mg
Study: 24717698
Drug: Palonosetron 0.0050
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron 0.0050 mg
Study: 22450972
Drug: Ceftolozane-tazobactam (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftolozane-tazobactam (single dose)
Study: 22450972
Drug: Ceftolozane alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftolozane alone (multiple doses)
Study: 22450972
Drug: Ceftolozane-tazobactam (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftolozane-tazobactam (multiple doses)
Study: 18283076
Drug: Warfarin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin treatment arm
Study: 29556414
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy (CPT)
Study: 11394733
Drug: Extended-release oxybutynin
Normalized name: oxybutynin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release oxybutynin 10 mg
Study: 16415311
Drug: Tolterodine 2
Normalized name: tolterodine 2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine 2 mg
Study: 11394733
Drug: Immediate-release oxybutynin
Normalized name: oxybutynin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release oxybutynin 5 mg
Study: 9699222
Drug: Capsule A
Normalized name: capsule administration aid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule A (5 mg MT)
Study: 2524992
Drug: Baclofen, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen, 60 mg/day
Study: 28277874
Drug: HL301 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: HL301 0.6 g/day
Study: 28277874
Drug: HL301 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: HL301 1.2 g/day
Study: 28277874
Drug: All HL301
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All HL301 treatment groups
Study: 21680092
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral contraceptive therapy (COCT)
Study: 12596107
Drug: Topical testosterone
Normalized name: testosterone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical testosterone application (Testoviron, 2 mg/kg/wk for 3 weeks)
Study: 12596107
Drug: Intramuscular testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular testosterone injection (same preparation, weekly for 3 weeks)
Study: 10509041
Drug: Epirubicin/paclitaxel combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin/paclitaxel combination plus G‐CSF
Study: 2071350
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg ciprofloxacin 4 hr before surgery (group I)
Study: 2071350
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg ciprofloxacin 8 hr before surgery (group II)
Study: 2071350
Drug: Two 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 750 mg doses of oral ciprofloxacin every 12 hr, last dose 12 hr before surgery (group III)
Study: 21914118
Drug: Interlaminar (IL)
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interlaminar (IL) epidural steroid injection
Study: 11073753
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate (13.3 mg)
Study: 11073753
Drug: Zinc acetate
Normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc acetate (5 or 11.5 mg)
Study: 8250368
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of cefapirine intravenously every eight hours, four times, starting at induction of anaesthesia
Study: 18209674
Drug: 20% mannitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% mannitol solution (n = 10 patients)
Study: 18209674
Drug: 7.45% hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.45% hypertonic saline solution (HSS) (n = 10 patients)
Study: 16803420
Drug: Valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 80 or 160 mg/day
Study: 16803420
Drug: Valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 80 mg, 160 mg, or 160 mg plus hydrochlorothiazide
Study: 14763352
Drug: H2-receptor antagonists
Normalized name: H2-receptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2-receptor antagonists (H2-RA) at double-dose
Study: 14763352
Drug: Standard doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doses of H2-RA
Study: 10982217
Drug: Antihistamine alone
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamine alone (n = 13)
Study: 10982217
Drug: Antihistamine in
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamine in combination with intranasal corticosteroid (n = 13)
Study: 2877875
Drug: Ketamine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (2 mg kg‐1) and alcuronium, supplemented by N2O‐O2 (Group KA)
Study: 2877875
Drug: Ketamine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (2 mg kg‐1) and alcuronium, supplemented by N2O‐O2 and 0.5% halothane (Group KAH)
Study: 25216543
Drug: Standard short
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard short infusion (1g imipenem/1g cilastatin over 30min three times daily)
Study: 20686499
Drug: Olmesartan (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan (10-40 mg) plus amlodipine (5 mg) for 8 weeks
Study: 20686499
Drug: Olmesartan (up-titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan (up-titrated to 20/5, 40/5 or 40/10 mg) plus amlodipine (5 mg)
Study: 20686499
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 mg) monotherapy
Study: 2563743
Drug: Terfenadine, 60
Normalized name: Terfenadine, 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine, 60 mg taken twice daily
Study: 8621847
Drug: Loratadine, 10
Normalized name: Loratadine, 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine, 10 mg once daily
Study: 25056227
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate nasal spray (FFNS) 55μg, once daily for two weeks
Study: 9769027
Drug: Propentofylline (PPF)
Normalized name: propentofylline
DrugBank: Propentofylline (DB06479)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propentofylline (PPF) 300 mg t.i.d. for 12 weeks
Study: 2677423
Drug: Various active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various active treatments for non-small-cell lung cancer
Study: 2677423
Drug: Various active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various active treatments for small-cell lung cancer
Study: 329743
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of mianserin
Study: 329743
Drug: mianserin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: mianserin + alcohol (0.5 g/kg)
Study: 9205765
Drug: ebrotidine 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: ebrotidine 800 mg
Study: 7708637
Drug: Intramuscular isoniazid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular isoniazid, pyrazinamide+rifampicin
Study: 7708637
Drug: Long-term treatment
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term treatment (12 months and more) with all tuberculostatic agents and surgical intervention
Study: 3308720
Drug: Ceftazidime (80‐100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (80‐100 mg/kg/day)
Study: 3308720
Drug: Netilmicin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netilmicin (6 mg/kg/day)
Study: 24633406
Drug: Gradual tapering
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gradual tapering of clopidogrel maintenance therapy over four weeks
Study: 24633406
Drug: Abrupt discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abrupt discontinuation of clopidogrel therapy after continued therapy for an additional four weeks
Study: 18808445
Drug: Morphine 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.05 mg/kg
Study: 8915035
Drug: Donepezil 5
Normalized name: donepezil 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 5 mg/day
Study: 10232717
Drug: Propofol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2.5 mg x kg(‐1))
Study: 10232717
Drug: Etomidate (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (0.3 mg x kg(‐1))
Study: 2257858
Drug: Nifedipine 5
Normalized name: nifedipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 5 mg
Study: 1938849
Drug: Nifedipine 15
Normalized name: nifedipine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 15 mg
Study: 2257858
Drug: Nicardipine 20
Normalized name: nicardipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 20 mg
Study: 2350528
Drug: Nicardipine 30
Normalized name: niCARdipine 30 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 30 mg
Study: 6805361
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg morphine in 1 ml saline + 6 ml bupivacaine 0.5%
Study: 6805361
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg morphine in 1 ml saline + 6 ml bupivacaine 0.5%
Study: 6805361
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg morphine in 6 ml saline
Study: 28849623
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) iron sucrose
Study: 30074935
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous sulfate
Study: 24717794
Drug: TAA‐AQ (triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAA‐AQ (triamcinolone acetonide aqueous nasal spray, 110 μg for 2-11 years old or 220 μg for 6-11 years old)
Study: 24717794
Drug: TAA‐AQ (triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAA‐AQ (triamcinolone acetonide aqueous nasal spray)
Study: 18996033
Drug: 1.7 mL
Normalized name: DENOSUMAB 120 MG/1.7 ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.7 mL of 4% articaine/HCl injected into the buccal vestibule
Study: 17617286
Drug: C.E.R.A. administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: C.E.R.A. administered at one of three doses (0.25 pg/150 IU, 0.4 pg/150 IU, or 0.6 pg/150 IU) with frequency subgroups of QW or Q2W.
Study: 15359376
Drug: Clomethiazole (1st
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomethiazole (1st day: 3 x 384 mg, 2nd day: 4 x 384 mg, 3rd day: 3 x 384 mg, 4th day: 2 x 384 mg, 5th day: 1 x 384 mg)
Study: 28720132
Drug: IND/GLY 110/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: IND/GLY 110/50 μg q.d.
Study: 15870668
Drug: Glutamine supplement
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine supplement (0.6 g.kg ‐1 .d ‐1)
Study: 15870668
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no glutamine supplement)
Study: 7880409
Drug: Ketorolac gel
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac gel
Study: 3066339
Drug: PGI2 infusion
Normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGI2 infusion (4 to 12 hours daily)
Study: 31705683
Drug: Probiotic group
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic group receiving drops and lozenges containing L. reuteri (ATCC PTA 5289 & DSM 17938)
Study: 25554404
Drug: Eplerenone 25
Normalized name: eplerenone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 25 mg orally every other day for the first month and once daily thereafter, in addition to background therapy with ACEI or ARB.
Study: 22961092
Drug: Cranberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry juice (UR65), 125 mL once daily for 24 weeks
Study: 22961092
Drug: Placebo beverage,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo beverage, 125 mL once daily for 24 weeks
Study: 16011136
Drug: Pterygopalatine fossa
Normalized name: Fossaoprin SPG2 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pterygopalatine fossa infiltration with 2 mL of 2% lidocaine and 1:80,000 adrenalin
Study: 10090355
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g of alcohol
Study: 10090355
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g of alcohol
Study: 28514235
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg intravenous pretreatment)
Study: 24237724
Drug: Aloe vera
Normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloe vera gel (n = 15 per category)
Study: 19097758
Drug: Ertapenem 1
Normalized name: ertapenem 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertapenem 1 g intravenous dose
Study: 9551674
Drug: GM-CSF alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF alone (65-250 microg/m2 three times weekly for 6 months)
Study: 9551674
Drug: Interferon alone
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alone (3 mU three times weekly for 6 months)
Study: 9551674
Drug: Interferon +
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon + GM-CSF (3 mU + 250 microg/m2 three times weekly for 6 months)
Study: 20652004
Drug: GM-CSF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF treatment
Study: 7358200
Drug: Loxapine (10-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxapine (10-150 mg/day)
Study: 7358200
Drug: Thioridazine (150-750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thioridazine (150-750 mg/day)
Study: 20940383
Drug: Placebo implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo implants (4 implants)
Study: 20940383
Drug: Buprenorphine implants
Normalized name: buprenorphine Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine implants
Study: 18426577
Drug: Relora (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relora (250 mg capsules, 3 times daily for 6 weeks)
Study: 14582585
Drug: Triclosan-containing dental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triclosan-containing dental gel (0.3%) applied for 5 min twice daily for 14 days
Study: 10757567
Drug: Oxycodone-thiopental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone-thiopental
Study: 15366589
Drug: Huannao Yicong
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huannao Yicong capsule (HYC) 3 capsules, 3 times daily for 2 months
Study: 10024707
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (ear electroacupuncture with two needles at an active site and self-retained ear seeds for two weeks)
Study: 10024707
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (ear electroacupuncture with two needles at a placebo site and self-retained ear seeds for two weeks)
Study: 7981930
Drug: Colestipol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestipol (10 g)
Study: 23199101
Drug: Total arch
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total arch distalization using orthodontic mini‐implants (OMIs) combined with interproximal stripping (IPS)
Study: 16482236
Drug: Standard volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard volume PEG (4 L PEG)
Study: 8149110
Drug: d-fenfluramine (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-fenfluramine (45 mg/day)
Study: 26471280
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group with printed symptom summaries available before each weekly office visit
Study: 16287954
Drug: High-dose atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose atorvastatin (80 mg/d)
Study: 17606955
Drug: Low-dose atorvastatin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose atorvastatin (10 mg/d)
Study: 10052024
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg intravenous)
Study: 7887644
Drug: Arm A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A: 250 mg/m2 of l‐LV and 600 mg/m2 of 5‐FU weekly
Study: 7887644
Drug: Arm B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B: 100 mg/m2 of l‐LV and 370 mg/m2 of 5‐FU for 5 consecutive days
Study: 7887644
Drug: Arm C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm C: 10 mg/m2 of l‐LV and 370 mg/m2 of 5‐FU for 5 consecutive days
Study: 2403824
Drug: Native prothrombin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Native prothrombin antigen (therapeutic range, 12 to 24 micrograms/mL)
Study: 240140
Drug: Alclofenac 500
Normalized name: Acéclofénac
DrugBank: Aceclofenac (DB06736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alclofenac 500 mg
Study: 29202730
Drug: Biomarker-guided antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomarker-guided antibiotic treatment of stroke associated pneumonia
Study: 23707824
Drug: Internet counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet counseling (daily e-mails with recommended activities through Pfizer's GetQuit program)
Study: 23480640
Drug: Once-daily darunavir/ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily darunavir/ritonavir (DRV/r) 800/100 mg
Study: 22189150
Drug: Lopinavir/ritonavir 800/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir 800/200 mg
Study: 6360815
Drug: Propranolol (non‐selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (non‐selective beta 1 and beta 2 blocker)
Study: 6360815
Drug: Prazosin (alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (alpha blocker)
Study: 6360815
Drug: Atenolol (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (selective beta 1 blocker)
Study: 27636923
Drug: Pulmonary rehabilitation
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmonary rehabilitation (PR) cycle in addition to standard therapy for COPD
Study: 9663842
Drug: Ranitidine effervescent
Normalized name: ranitidine Effervescent Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine effervescent tablets 150 mg
Study: 9663842
Drug: Ranitidine effervescent
Normalized name: ranitidine Effervescent Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine effervescent tablets 300 mg
Study: 9663842
Drug: Famotidine fast-dissolving
Normalized name: melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Famotidine fast-dissolving tablets 20 mg
Study: 9663842
Drug: Omeprazole capsules
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole capsules 20 mg
Study: 27189295
Drug: Dexmedetomidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.5 μg/kg) for 5 minutes
Study: 27189295
Drug: Remifentanil with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil with an effect site concentration of 1.5 ng/mL until endotracheal extubation
Study: 25213871
Drug: Best physician's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best physician's choice (BPC) chemotherapy
Study: 22700854
Drug: Dabigatran 110
Normalized name: dabigatran 110 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran 110 mg (urgent surgery)
Study: 22700854
Drug: Warfarin (urgent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (urgent surgery)
Study: 17140102
Drug: Gene and
Normalized name: lipid nanoparticle encapsulating single guide RNA (G012267) targeting the human KLKB1 gene and messenger RNA (mRNA000042) encoding Cas9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene and cell therapy aimed at stimulating angiogenesis
Study: 22464408
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (OC)
Study: 9351415
Drug: Non-users of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-users of oral contraceptives
Study: 8931610
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (n = 416)
Study: 21102369
Drug: Subconjunctival lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subconjunctival lidocaine injection
Study: 20570360
Drug: Subconjunctival lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subconjunctival lidocaine injection (crossover group)
Study: 20570360
Drug: Sham injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injection (crossover group)
Study: 8915574
Drug: Increased levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased levels of trkA receptors in astrocytes in the CA1 region of Alzheimer's disease hippocampi, associated with beta-amyloid-positive plaques.